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Abstract
The Mexican axolotl, Ambystoma mexicanum, carries the naturally-occurring recessive mutant gene
'c' that results in a failure of homozygous (c/c) embryos to form hearts that beat because of an
absence of organized myofibrils. Our previous studies have shown that a noncoding RNA,
Myofibril-Inducing RNA (MIR), is capable of promoting myofibrillogenesis and heart beating in the
mutant (c/c) axolotls. The present study demonstrates that the MIR  gene is essential for
tropomyosin (TM) expression in axolotl hearts during development. Gene expression studies show
that mRNA expression of various tropomyosin isoforms in untreated mutant hearts and in normal
hearts knocked down with double-stranded MIR (dsMIR) are similar to untreated normal.
However, at the protein level, selected tropomyosin isoforms are significantly reduced in mutant
and dsMIR treated normal hearts. These results suggest that MIR is involved in controlling the
translation or post-translation of various TM isoforms and subsequently of regulating cardiac
contractility.
Introduction
The Mexican axolotl, Ambystoma mexicanum, has proven to
be a unique animal model in the study of cardiac develop-
ment. The axolotl (a neotenous salamander) carries a nat-
urally occurring recessive mutation, gene c, first
discovered and characterized by Humphrey [1], which
results in abnormal cardiac development in homozygous
recessive "c/c" embryos. The mutant embryonic hearts
develop, but fail to beat, making them distinguishable
from normal embryonic hearts which start to beat at stage
35. The myocytes of the mutant hearts fail to form organ-
ized myofibrils and the embryos survive only to stage 42,
the hatching stage, due to a lack of circulation.
Among the various myofibril structural proteins, tropo-
myosin has been shown by SDS-PAGE [2], radio-immu-
noassay [3], 2D gel electrophoresis [4] and
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confocal microscopy of whole hearts to be drastically
reduced in the mutants [5-7]. Interestingly, other myofi-
bril structural proteins such as actin, myosin and myosin
binding protein C, however, were found to be at or near
normal levels in the mutant hearts [8-10].
Using this animal model, Myofibril-Inducing RNA (MIR),
a small bioactive RNA, was shown in previous studies to
be able to restore tropomyosin protein synthesis, promote
myofibrillogenesis, and initiate heartbeat in the mutant
embryonic hearts in organ culture [11]. The MIR appears
to function through its unique secondary structure since it
is a non-coding RNA [7,11].
In mammals, birds and amphibians, altogether four dif-
ferent types of tropomyosin genes have been identified:
alpha gene (TPM1), beta gene (TPM2), gamma gene
(TPM3) and TM4 type gene (TPM4) [12]. More recently,
TM4, a cytoskeletal tropomyosin, also has been associated
with growth and regeneration in response to injury, dis-
ease state and stress in skeletal muscle of mouse and
humans [13]. Moreover, in zebrafish embryos, a heart
specific isoform of TM4 is essential for normal myofibril
formation and developing a heartbeat [14]. In addition, it
has been found recently that tropomyosin is likely neces-
sary for actin filament formation in motile cells that
employ lamellipodia and filopodia for locomotion [15].
Thus, tropomyosin appears to play a major role in actin
filament modulation and contractility in both muscle and
nonmuscle contractile systems. Striated muscle-specific
alpha-tropomyosin is the predominant isoform in cardiac
muscle, with low levels of beta-tropomyosin expressed
during fetal development in the mouse heart [16]. In
amphibian models, such as Xenopus, the cardiac muscle
tropomyosins are synthesized from the alpha-TM and TM-
4 genes [17]. In all of these animal models, the alpha-tro-
pomyosin gene is the major contributor to the tropomy-
osin proteins in the cardiac myofibril structures.
There are at least three striated muscle isoforms of tropo-
myosin present in the axolotl. Two isoforms of tropomy-
osin cDNA have been identified which apparently are
derived from the single alpha-tropomyosin gene (TPM1)
through alternative splicing [18]. Spinner et al. [19]
cloned another tropomyosin cDNA which is the product
of a TM4 type tropomyosin gene from axolotl heart. Our
results from the axolotl model of heart development are
consistent with the findings in Xenopus in that both alpha
(ATmC-1 and ATmC-2) and TM4 type (ATmC-3) tropo-
myosin transcripts are expressed in axolotl hearts [18,19].
In the present studies, we conducted a series of experi-
ments to further understand the role of MIR in the expres-
sion of tropomyosin and myofibrillogenesis using our
mutant axolotl heart model. First, we have cloned the full-
length cDNA sequence of MIR. Sequence analyses suggest
that MIR is a noncoding RNA molecule. However, func-
tional studies indicate that the MIR is essential for tropo-
myosin expression as well as myofibrillogenesis in axolotl
hearts during development at the level of translation or
post-translation.
Materials and methods
Procurement of animal tissues
The embryos used in the study were derived from adult
animals maintained in our colony. We followed NIH
Guidelines for the Care and Use of Laboratory Animals
and all animal protocols were approved by the Institu-
tional Animal Care and Use Committee. Embryos at
stages 35-38 were collected and dissected in Steinberg's
solution (SS) as described previously [20]. The inner tho-
racic cavities were exposed and the hearts removed and
used in the various bioassays.
Bioassays with cationic liposome transfection and 
confocal microscopy
Liposome reagents (0.1-0.16 μg/μl) and MIR sense (500
nt) (0.022 μg/μl), antisense RNA (500 nt) (0.022 μg/μl)
or dsRNA (500 bp, 0.002 μg/μl) were diluted in SS with-
out antibiotics for 30-45 minutes at room temperature
(RT). The two solutions were mixed and drops of transfec-
tion solution were prepared. The hearts are transferred
with SS into drops containing the transfection solution for
a total volume of 20 μl and appropriate concentrations of
RNAs (7 ng/μl) or double-stranded RNA (4 ng/μl), and
lipofectin. 10× of SS was added to the transfection
medium to dilute the liposome reagents after 24 hours
and the hearts were cultured for an additional 2 days (for
mutant hearts + MIR RNA) or an additional 9 days (for
normal hearts + dsRNA) in a 17°C incubator. The hearts
were stained for immunofluorescent observation and ana-
lyzed by confocal microscopy following our previously
published procedures [7,21,22].
Synthesis of double-stranded MIR
Sense and antisense MIR are synthesized in vitro using T7
RNA polymerase (Ambion, TX) on PCR generated MIR
cDNA templates with T7 promoter added to either 5' or 3'
end sequences. 20 μg of both sense and antisense RNA are
mixed in annealing buffer (pH 7.4) and denatured at
68°C for 5 minutes. Sense and antisense RNAs are
annealed to each other to form dsRNA by gradually reduc-
ing the temperature to 25°C. The products were run on
1.5% agarose gels and the dsRNA was recovered from the
gels. FITC-labeled dsRNA was synthesized as described
above but using 1:3 FITC-conjugated UTP and unlabeled
UTP for single-stranded RNA transcription.Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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Real-time RT-PCR
Stage 36/37 normal and mutant embryonic hearts are
explanted into 15 μl droplet cultures of Steinberg's buff-
ered salt solution containing antibiotics [20]. Mutant
hearts are treated with 40 ng/heart MIR sense (166 nt) or
MIR antisense (166 nt) and incubated at 14°C for 36
hours or 72 hours. Each treatment group consisted of 40
hearts. As controls, 40 normal and 40 mutant hearts are
left untreated. The total RNA is extracted from the axolotl
hearts using TRI Reagent (Sigma). Reverse transcription is
performed using the Thermoscript RT system from Invit-
rogen, CA. Quantitative PCR is performed in a Lightcycler
system using a Roche's Fast Start SYBR Green I Kit, follow-
ing our published methods [23]. The primers were
Table 1: Primers used for different genes in real time RT-PCR experiments.
Gene Forward/Reverse Primer Sequence Product Size
ATmC-3 Forward 5'-ggagcttgaccatgcgctgaa 200
ATmC-3 Reverse 5'-tgagaaccgacacaaagcaagagg
ATmC-exon2a Forward 5'-gcgtgacagggtgctggatgaac (P5) 154
ATmC-exon2b Forward 5'-tgaagggtaccgaggacgagttgga (P3)
ATmC-exon3 Reverse 5'-ccagacgctcctgagcacgatcc (P4)
ATmC-exon345 Forward 5'-gagcgtctggccacagccctaca (P1) 233
ATmC-exon345 Reverse 5'-tcttccgcacgctccagatcacc (P2)
ATm5- Forward 5'-gccacacctacctgcgagtgttcc 249
ATm5- Reverse 5'-gacgctcctgagcacgatccaac
MIR Forward 5'-ttccacccactcgagcgtcaaca 158
MIR Reverse 5'-gctcggatatgcgtgcaaccttga
cTnT Forward 5'-ccaagggcttcaccgggctcaa 173
cTnT Reverse 5'-tggcagaggtggaatggatcacagg
α-syntrophin Forward 5'-ggactctccaccgcctccctctc 208
α-syntrophin Reverse 5'-ccccgcttcatccttcgctctga
β-syntrophin Forward 5'-gacttggcttggtgggctgaacg 243
β-syntrophin Reverse 5'-aggccattcagttgcagggtgct
Msx1 Forward 5'-tgtacgccgctcacatgggctac 220
Msx1 Reverse 5'-ccctcttcctgccaccgaatcac
Msx2 Forward 5'-ggaagggaagggaaggcagaacg 215
Msx2 Reverse 5'-tccacgaatcagggcgttgtttg
β-actin Forward 5'-tccatgaaggctgcccaact 210
β-actin Reverse 5'-tggcgccacatctgattgatJournal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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designed by the Primer 3 program from the Massachusetts
Institute of Technology as listed in the Table 1.
Cloning of exon 1b sequence for axolotl alpha-TM
We have cloned exon 1b of the axolotl alpha-TM. 5'RACE
experiments using primers designed from the exon 3
sequence of the axolotl alpha-TM (ATmC1-exon3-rev-1:
5'-CCAGACGCTCCTGAGCACGATCC; ATmC1-exon3-
rev-2:5'-CCAGCTGGATACGCCTGT TC) and a 5' adaptor
sequence revealed both PCR bands corresponding to the
ATmC-1 sequence and a shorter PCR band after agarose
gel electrophoresis. The shorter band was cloned into a
pGEM-T easy vector (Promega, WI) and sequenced. The
sequence shows high homology to the 5' ends of alpha-
TM5a or 5b from other vertebrates. The sequence is: 5'-
GTACTGTTGAGGCATCCACGTCTTCACTATTACT-
GGGGCATTTGTAGTCCCTTGGAATTTGAG CTGACCT-
TATCGCTACTCGCCTCATATGATAGAGGCGCCACACCT
ACCTGCGAGTGTTCCGTT CCCCGGCCCTCAGCAT-
GTCTGGGGGCACCTCCCTGGAAGCGGTGCGGCG-
GAAGATCCGCGC
CCTGCAGGAGCAGGCGGACTCCGCTGAAGCCCG-
GGCGTGTAGCCTGCAGCGGGAACGAGAC GCT-
GAGCGGCAGCTGCGAGAGGCGGCTGAGAGTGATGTA
GCCTCCCTGAACAGGCGTATCCA GCTGGTTGAGGAA-
GAGTTGGAT CGTGCTCAGGAGCGTCTGG. The bolded
ATG represents a putative translation start site. The cloned
sequence corresponding to exon 3 shows 100% identity to
alpha-TM but with variations to axolotl ATmC-3, demon-
strating the origin of this fragment from axolotl alpha-TM.
We have named this isoform ATm5.
Two-dimensional gel electrophoresis and Western blotting
Isoelectrical focusing
The immobilized pH gradient (IPG) gel strips (pH range
3-6, 11 cm, Bio-Rad, CA) were rehydrated in 200 μl Read-
yPrep Rehydration/Sample Buffer that contained heart
samples for 12 hours. Isoelectric focusing (IEF) was per-
formed on the rehydrated IPGs at 20°C in three steps: 250
volts for 20 minutes, 8,000 volts for 2.5 hours, and then
20,000 Volts/hour using Protean IEF Cell system (Bio-
Rad, CA).
Two-dimensional SDS-PAGE
After isoelectrical focusing was completed, IPG strips were
prepared for SDS-PAGE using 12% Bis-Tris precast gels
(Bio-Rad, CA). The strips were then rinsed with electro-
phoresis running buffer (pH7.7) and laid into the two-
dimensional well of 12% precast gels and were run at 200
V for 1 hour following the manufacturer's protocol (Read-
yPrep™ 2-D Starter Kit; Bio-Rad, CA.).
Western blotting
The two-dimensional SDS-PAGE gels were transferred to
nitrocellulose membranes and processed for hybridiza-
tion. The membranes were incubated with CH1 mono-
clonal antibody (1:5000) (from Developmental Studies
Hybridoma Bank, University of Iowa) at a 1:2000 dilution
for 1 hour at RT. After two washings for 5 minutes each,
they were hybridized with horseradish peroxidase-conju-
gated mouse antihuman IgG (Amersham-Pharmacia Bio-
sciences) at 1:5000 dilution for 1 hour at RT and the blots
were washed and exposed to X-ray film and developed
with an ECL chemiluminescence system [22].
Results
Cloning the full length cDNA of the myofibril-inducing 
RNA (MIR) gene
We have previously published the nucleotide sequence of
the 166 nt long bioactive MIR [11] and showed that the
artificially synthesized 166 nt RNA can promote myofibril
formation and initiate beating of the mutant hearts in
organ culture studies [11].
To determine the full length sequence of the MIR gene, we
carried out experiments using a cDNA lambda phage
library from axolotls at stage 15-17 as well as an axolotl
genomic library (Stratagene, TX). Primers were designed,
based both on vector flanking sequences and the 166 bp
known fragment of the MIR. The PCR products were con-
firmed by Southern blotting assays. The promising PCR
bands were then sub-cloned into pGEM-T vectors
(Promega, WI) and subsequently sequenced. Primers
were designed again based on the new sequence and PCRs
were repeated (Table 1). By using genomic walking we
have extended the 5'-end of the original 166 bp MIR to
~700 bp. Starting from the original 166 bp MIR known
sequence, we also have performed 5' RACE reactions
using a Smart RACE Kit (Ambion, TX). Results show that
the full length of the MIR is expressed beginning at G
(380th base) within the genomic sequence (Fig. 1). In
addition, 3' RACE reactions have revealed about 150 nt
poly-A tail attached at the 3' end of the MIR (Fig. 1). We
believe that we have successfully cloned the full length
MIR. The nucleotide sequence of MIR has been deter-
mined and found to be unique because there is no signif-
icant homology with other known sequences available
from the gene databases. Moreover, there is no relatively
large open reading frame in the full-length sequence, indi-
cating that the MIR may be functioning directly through
its RNA structure, rather than a translation product. Inter-
estingly, eukaryotic promoter prediction software
(ExPASy: http://ca.expasy.org/tools/) has localized a
potential promoter in the 5' genomic sequence with a
conserved TATA box, 28 bp from the transcription start
site (Fig. 1). Our recent data using the Luciferase reporter
gene system (Promega, WI) have verified the transcription
driving ability of this potential promoter. We have cloned
nearly 3 kb of the upstream regulatory sequence in addi-
tion to the promoter sequence shown in Fig. 1. Serial dele-Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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tions of the promoter have been inserted into the
Luciferase reporter vectors and expression of these pro-
moters has been confirmed by transfecting into rat neona-
tal cardiomyocytes in culture (our unpublished data).
Full length MIR promotes tropomyosin protein expression 
in cardiac nonfunction mutant embryonic hearts
In vitro synthesized sense RNA from the full length (570
nt) MIR gene showed significant rescuing ability of the
mutant hearts (Fig. 2). Three days after sense MIR transfec-
tion, all of the 40 dissected mutant hearts showed positive
tropomyosin staining (Fig. 2C) while antisense RNA
transfection showed only background levels of staining
(Fig. 2D). Pretreatment of the MIR sense RNA with RNase
before transfection into the mutant hearts totally abol-
ished the activity of the sense RNA in promoting tropomy-
osin expression (Fig. 2E). It is clear that the bioactivity of
promoting tropomyosin expression in the mutant hearts
is due specifically to the sense MIR. These results are in
total agreement with our previous findings using the short
version of the MIR (166 nt). The full length 570 nt RNA
used for transfection in current experiments is at the same
molar concentration as the 166 nt RNA we used for previ-
ous studies [7,11]. Since the original 166 nt RNA (partial
sequence from MIR gene) is sufficient for the rescuing of
mutant hearts (Fig. 2F) [7,11], we believe that the 166 nt
partial sequence probably is the functional bioactive unit
in the MIR gene.
MIR-promoted tropomyosin protein expression in the 
mutant hearts is not due to increased transcription levels 
or splicing pattern changes of tropomyosin genes
To determine whether MIR-promoted tropomyosin pro-
tein expression in the mutant heart is due to regulation at
the transcriptional levels or changes in the splicing pat-
terns of the TM transcripts, we proposed two hypotheses.
The full length sequence of the MIR gene Figure 1
The full length sequence of the MIR gene. Genomic DNA sequence: 1-379 bp (Underlined); Active MIR sequence (166 
nt): 691-856 bp (Bold and underlined); Potential polyadenylation signals: 835-840 bp and 840-845 bp; Predicted TATA box: 
343-350 bp (Shaded); Longest predicted open reading frame: 659-808 bp; Poly A+: 977-1000 bp.
CTCGATCAGCAAACTTCTTTTTGCACCATCTTCAAATGCTTCTGTGTATC 50 
TTAAGGATAGCATCACAAGGTGTATACCCCAGGATGGAACATTGGATCTA 100 
AGGAGGATCACAGACTAGTCATACCTGGAACGCTCTGTCAGACCAGAGGA 150 
CATAAAAGACTTTCAGGTTTGAGACGCAGACGTTGGAATGAGTTGCCCAA 200 
GTTCTGCTCATGACAACACCTGCTTTCAGGCCCCTGTTGGAGCATCATCT 250 
GTTCAGGTAGGTGTTCATTAATGGTCTCTAGCAGACCCAAGATCAGTGTG 300 
CACAAGCACATGATTTCACAAAGGTGATATATGGGTAGGTTCTATGTAAA 350 
AACACTGCAAATTCCTAACATCACCCAATGTTCAAAAATAACATTTTAAT 400 
TTTGTATCTCCTAATACAGCCATCATAACATATTCTAGGACTGGTATAAC 450 
TGTATAGACAAACTCCCTTCCTAGGATATTTTGGGAAAGTGCTGGATAGC 500 
CGGGGAGAACAGCACCTTTCTCTCAGGCAATGTTAAATAGGTGCAATGTT 550 
TTCACATGTTATGGAATATATCTTCCAACTGACTGACCAAGAGAAAACAA 600 
TGAACCACAATACCGGAAACTTCATTCGTTTGACCCTTCCACCCACTCGA 650 
GCGTCAACATGCCCAGGCCGCTACCCCTTGACACACGTGTAGCACCACTC 700 
CATTTTTGGAACACCTCCTCTACCGTGGATGAGAGGCGGAGCCGATCCTT 750 
TGGAATTTGTACATGTGACCTCAAGGTTGCACGCATATCCGAGCAGTTGC 800 
TGGATTAGAGCAGGCACTCCCTTATCGGCTTTGGAATGGAGACCAGAAAG 850 
AACAATGTGGGACAGCTGATATGGAGGGCAGGGCGGGGAAGTGAGAGAAA 900 
GGGCAACAATAGAGGGCAGATAAAGGGGGGAGGGCAAGGAATAAACAGGA 950 
ACTGCAGTGGGAGAAAACGTCGAACGAGAAAAAAAAAAAAAAAAAAAAAA 1000 Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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Confocal microscopy of embryonic axolotl hearts stained with anti-tropomyosin antibody Figure 2
Confocal microscopy of embryonic axolotl hearts stained with anti-tropomyosin antibody. Normal heart incu-
bated with Steinberg's solution and lipofectin only has extensive tropomyosin staining (A). Mutant heart incubated with Stein-
berg's solution and lipofectin only has virtually no staining (B). Mutant heart incubated with Steinberg's solution, lipofectin and 
full length sense MIR shows significant tropomyosin (arrow) staining (C). Mutant heart incubated with Steinberg's solution, lipo-
fectin and full length sense MIR pretreated with RNase. Very little tropomyosin is indicated in the cells (D). Mutant heart incu-
bated with Steinberg's solution, lipofectin and full length antisense MIR. No staining for tropomyosin is observed (E). Mutant 
heart incubated with Steinberg's solution, lipofectin and 166 nt MIR RNA shows significant levels of tropomyosin (arrow) pro-
tein (F); Magnification: 60 ×.Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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We tested those hypotheses by performing a series of real-
time RT-PCR experiments.
Our first hypothesis proposes that for the MIR to promote
tropomyosin protein expression, it must increase the
expression of one or both of the tropomyosin genes
(alpha-tropomyosin and TM4 type) at the transcription
level. For the real-time RT-PCR experiments, we designed
primer pairs to amplify the alpha-tropomyosin and TM4
type tropomyosin genes selected from the common exon
sequences whose products represent the total transcripts
of each gene (Table 1). For alpha-TM, primers (ATmC-
345-for and ATmC-345-rev) are designed in the Exon 3, 4
and 5 regions which are common to all alpha-TM tran-
scripts [24,25]; for TM4 type tropomyosin, primers
(ATmC-3-for and ATmC-3-rev) are designed in the 3' UTR
region (Fig. 3A, B). Our real-time PCR results clearly show
that there is no significant difference between alpha-tro-
pomyosin or TM4 type tropomyosin RNA transcripts in
normal (+/+), mutant (c/c), sense MIR- and antisense
MIR- treated mutant embryonic hearts (stage 37-38) at
two different time periods of the transfection of MIR (Fig.
4A1, A2). These results clearly demonstrate that the MIR
does not perform a regulatory function at the transcrip-
tional level, thus disproving the first hypothesis.
Our second hypothesis proposes that the MIR regulates
splicing of tropomyosin transcripts to produce correct iso-
forms in the cardiac muscle cells. For these real time RT-
PCR studies, we designed specific primer pairs based on
representative alternative spliced exons of the alpha-tro-
pomyosin gene. From our previous studies, we found that
both ATmC-1 and ATmC-2 cDNAs are expressed from the
same alpha-tropomyosin gene but differ in exon 2, with
ATmC-1 containing a striated muscle specific exon 2b
while ATmC-2 contains a smooth muscle isoform specific
Schematic representation of four different TM isoforms produced from alpha -TM (A) and TM4 type tropomyosin (B) genes Figure 3
Schematic representation of four different TM isoforms produced from alpha -TM (A) and TM4 type tropomy-
osin (B) genes. Each box represents an exon which is joined together by mRNA splicing. The alpha-TM gene is alternatively 
processed at both the 5' and/or 3' ends, as well as at the internal exons 6a/b. Our studies are focused on the 5' end sequence 
and exon 2a/b. The fibroblast type tropomyosin isoform (ATm5) has only the 5' sequence cloned with exon 1b and part of 
exon 3 cloned for RT-PCR studies, assuming the internal and 3' sequence are homologous to other vertebrates (dashed line 
box). Primers to amplify specific isoforms were designed based on the alternative spliced exons (P1 to P5). C. Highly conserved 
peptide sequence from exon 1b of axolotl alpha-tropomyosin compared to other vertebrate sequences. The indicated splicing 
pattern of axolotl tropomyosin genes are hypothetical based on other vertebrate sequences. ATmC-1, 2 and 3 were all dem-
onstrated to be able to incorporate into myofibril structures [21].Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
Page 8 of 20
(page number not for citation purposes)
exon 2a (Fig. 3A). We have shown previously that both
ATmC-1 and ATmC-2 can be incorporated into cardiac
muscle fibers [21]. Alpha-TM has been reported also to
produce fibroblast tropomyosin isoforms with smaller
molecular weights, such as TM5a and TM5b, both of
which can be incorporated into myofibrils [25]. Isoforms
TM5a and 5b are produced by using an internal promoter
located between exon 2b and exon 1b thus skipping exon
2a and exon 2b and conjoining exon 1b and exon 3
directly together [26]. To determine whether MIR can reg-
ulate the expression pattern of tropomyosin by selectively
favoring the use of exon 1b, 2a or 2b, we have cloned exon
1b of the axolotl alpha-TM to study the Axolotl Tm5 gene
(ATm5). 5' RACE experiments using primers designed
from the exon 3 sequence of axolotl alpha-TM and a 5'
adaptor sequence revealed PCR bands corresponding to
the ATmC-1 sequence and a shorter PCR band by agarose
gel electrophoresis. The shorter PCR band was gel purified
and cloned into T-vectors (Promega, WI). Sequencing
results demonstrated a highly conserved sequence of axol-
otl alpha-TM exon 1 compared to other vertebrates (Fig.
3C). We then designed different primer pairs based on the
alpha-TM exon 1b, 2a and 2b sequences (Fig. 3A). Real-
time RT-PCR was performed on normal, mutant, MIR
sense and antisense RNA-treated mutant embryonic
hearts using these primer pairs to compare alpha-TM
splicing patterns. Results from these experiments did not
support our second hypothesis. That is, the alpha-TM
splicing pattern at the 5' end is not regulated by the MIR.
Neither ATmC-1 (exon 2b included) nor ATmC-2 (exon
2a included) type splicing is altered with MIR treatment
(Fig. 4B1, B2). Similar quantities of splicing products also
were observed for fibroblast type tropomyosin with direct Figure 4
ATmC-1-345 (Alpha-Tm exon 345) mRNA Level
0
0.2
0.4
0.6
0.8
1
1.2
1.4
36A 36S 72A 72S +/+ -/-
Treatment
R
e
l
a
t
i
v
e
 
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
 
L
e
v
e
l
 
 
(
A
T
m
C
-
1
-
3
4
5
/
b
e
t
a
-
a
c
t
i
n
)
A1 
A2  A1 
ATmC-3 (TM4 tropomyosin) mRNA Level
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
36A 36S 72A 72S +/+ -/
Treatment
R
e
l
a
t
i
v
e
 
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
 
L
e
v
e
l
 
(
A
T
m
C
-
3
/
b
e
t
a
-
a
c
t
i
n
)
-
A2 
ATmC-1 (exon2b+exon3)
0
0.2
0.4
0.6
0.8
1
1.2
36A 36S 72A 72S +/+ -/-
Treatment
R
e
l
a
t
i
v
e
 
E
x
p
r
e
s
s
i
o
n
 
L
e
v
e
l
 
(
A
T
m
C
-
1
/
b
e
t
a
-
a
c
t
i
n
)
B1 
ATmC-2 (exon2a+exon 3)
0
0.5
1
1.5
2
36A 36S 72A 72S +/+ -/-
Treatment
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
 
(
A
T
m
C
-
2
/
b
e
t
a
-
a
c
t
i
n
)
B2 
ATm5 (exon1b+exon3)
0
5
10
15
20
25
36A 36S 72A 72S +/+ -/-
Treatment
R
e
l
a
t
i
v
e
 
E
x
p
r
e
s
s
i
o
n
 
L
e
v
e
l
 
(
A
T
m
5
/
b
e
t
a
-
a
c
t
i
n
)
B3 
Transcriptional levels of various tropomyosin isoforms (A1  and A2); Determination of mRNA splicing of various tropo- myosin isoforms (B1, B2 and B3) Figure 4
Transcriptional levels of various tropomyosin iso-
forms (A1 and A2); Determination of mRNA splicing 
of various tropomyosin isoforms (B1, B2 and B3). 
Real-time RT-PCR showed no significant difference at the 
transcription level for alpha- (A1) and TM4 type tropomyosin 
(A2) genes in the mutant hearts treated with MIR sense or 
antisense RNA. 36A: Mutant hearts treated with antisense 
MIR for 36 hours; 36S: Mutant hearts treated with sense MIR 
for 36 hours; 72A: Mutant hearts treated with antisense MIR 
for 72 hours; 72S: Mutant hearts treated with sense MIR for 
72 hours; +/+: homozygous normal hearts with no treat-
ment; (-/-): homozygous mutant hearts with no treatment. 
Real-time RT-PCR showing no significant difference during 
mRNA splicing of the alpha-TM gene (the ATmC-1 contain-
ing exon 2b (B1), the ATmC-2 containing exon 2a (B2) and 
the fibroblast tropomyosin isoform with direct exon 1b and 
3 conjunction (B3) in the mutant hearts treated with the MIR 
sense or MIR antisense.Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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exons 1b and 3 conjunctions in all normal, mutant, MIR
sense and antisense RNA treated hearts (Fig. 4B3).
Thus these studies reiterate that MIR-promoted tropomy-
osin expression in the mutant hearts is not due to
increased transcription levels or splicing pattern changes
in the tropomyosin genes.
Knockdown of MIR expression decreases sarcomeric 
tropomyosin protein resulting in the failure of myofibril 
formation in normal hearts
Our confocal immunofluorescence studies have proved
that MIR is sufficient to promote tropomyosin expression
and myofibrillogenesis in cardiac mutant hearts. To dem-
onstrate that the MIR is essential for normal embryonic
heart development in axolotls, double-stranded MIR (550
bp covering the full length) was synthesized as described
in the Materials and Methods section. Successful produc-
tion of double-stranded MIR (dsRNA) has been verified
by polyacrylamide gel electrophoresis (Fig. 5). Using the
same methods, we have also produced FITC-labeled
dsRNA. The high transfection efficiency using these dsR-
NAs was demonstrated by confocal microscopy. It showed
nearly 100% of the heart cells in the embryonic heart tube
were transfected using our transfection protocol. The dou-
ble-stranded RNA was purified from single stranded RNA
residue by agarose gel electrophoresis and was applied to
the cultured normal whole embryonic hearts. We found
that this RNA was effective in inhibiting the normal heart-
beat as determined by daily evaluation under a dissecting
microscope (Table 2). Monoclonal antibody staining
(CH1) for tropomyosin [7,27] in these double-stranded
RNA-treated hearts revealed disruption of myofibril for-
mation (Fig. 6).
The dissected normal hearts with mock transfection (no
RNA) showed abundant tropomyosin expression and
organized myofibrils easily detectable by confocal micro-
scopy even after 9 days in culture (Fig. 6A). Most double-
stranded MIR-transfected hearts (22 out of 30 total hearts
at stage 37) when dissected stopped beating after 4 days in
culture. Careful observation of these hearts under an
inverted microscope (× 200) revealed sporadic contrac-
tions in portions of the heart tube indicating that these
hearts have live tissue. We evaluated the viability of the
cells in the organ-cultured hearts by staining the whole
hearts with Trypan Blue. Interestingly, 9 out of the 22 ds
MIR-transfected hearts that had stopped beating, resumed
contraction activity after 6 days in culture although at a
decreased beating rate and strength, while the rest
remained quiescent for the duration of the experiment (9
days). Confocal microscopy on these hearts that stopped
beating and never regained their contractility after 9 days
in culture showed a significant disarray in the myofibril
structures and decreased levels of tropomyosin protein
expression (Fig. 6B), similar to the untreated mutant
hearts [7,21]. No rescuing effect was observed in the
mutant hearts transfected by ds RNA and also they
showed a negative staining pattern for tropomyosin
expression (Fig. 6C). A mock-transfected (no RNA) nor-
mal heart showed numerous cells positively stained by
tropomyosin antibody, CH-1 (Fig. 6D). Fig. 6E shows a
normal heart treated with double-stranded MIR. It clearly
showed significantly lower tropomyosin expression than
normal levels in the whole heart tube except for the conus
region, which showed a few positively stained cells.
Results are reminiscent of a similar staining pattern for
mutant hearts in our previously published study [21],
with negative staining for tropomyosin in the ventricle
but positive staining in the conus region. Since ds RNA
could be degraded by Nuclease S1 [28], we also included
a control group of normal hearts transfected with dsRNA
predigested with Nuclease S1 (Promega, WI) in our exper-
iments, to determine whether degraded double-stranded
RNA has any effect on normal heart beating. Interestingly,
after transfection with the degraded double-stranded
RNA, these hearts stopped beating temporarily (possibly
due to the damaging effects of RNases remaining in the
medium) but regained normal beating activity after an
additional 3 days in culture. Confocal microscopy showed
Double-stranded MIR Figure 5
Double-stranded MIR. Synthesized MIR double-stranded 
RNA loaded on 1.5% agarose gel for electrophoresis shows a 
550 bp band. The size marker is loaded on the left-side of the 
gel.Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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Confocal microscopy of embryonic axolotl hearts treated with double-stranded MIR Figure 6
Confocal microscopy of embryonic axolotl hearts treated with double-stranded MIR. The images show those 
hearts that stopped beating after 4 days but regained contractions later. Hearts were fixed after 9 days in culture. Normal 
heart (stage 36) organ cultured with lipofectin in Steinberg's Solution only for 10 days (A); Myofibril structures are clearly 
shown. Normal heart (stage 36) organ cultured with lipofectin in Steinberg's Solution with double-stranded RNA for 10 days 
(B); Mutant heart (stage 36) organ cultured with lipofectin in Steinberg's Solution with double-stranded RNA for 10 days (C). 
(Magnification: A-E: 60 ×; F and G: 10 ×). Hearts incubated with mock transfection (no dsRNA) show abundant staining of tro-
pomyosin and organized myofibril structures (D) with nuclei stained by propidium iodide (PI). Hearts transfected by the 
dsRNA show a significant decrease of tropomyosin expression in more than half of the cells but continue to express in the 
remaining cells (E). Normal hearts treated with dsRNA for 9 days stained for tropomyosin (F). Clusters of cells with positive 
staining for tropomyosin are present in different areas. Normal hearts with mock transfection (no dsRNA) for 9 days stained 
for tropomyosin (G).
     
 
     
Table 2: Percentage of beating hearts at different time points after ds RNA transfection.
Treatment Groups Day 0 (0 hr) Day 4 (96 hrs) Day 9 (216 hrs)
dsRNA treated group 100% 26.67% 46.67%
RNase-pretreated dsRNA treated group 100% 76.67% 70%
Steinberg's solution only group 100% 96.67% 76.67%Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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numerous positively-stained cells in these hearts which
appeared similar to untreated normal hearts after 9 days
in culture.
In the double-stranded MIR RNA treated normal hearts
that stopped beating after 3 or 4 days but regained con-
tractions after 9 days, confocal microscopy studies still
revealed decreased staining of tropomyosin protein (Fig.
6F) compared to mock transfected cells (Fig. 6G). Organ-
ized myofibrils with tropomyosin staining could be found
in a few sparsely distributed cells in the heart although the
overall numbers of stained cells were dramatically
decreased in the dsRNA-treated hearts (Fig. 6E) compared
to the control normal hearts without dsRNA treatment
(Fig. 6D). Since our whole-mount heart specimens are
usually 150-200 μm in thickness, we used epifluorescence
microscopy to view the fluorescence image of the whole
heart. Thus we were able to clearly observe the groups of
cells that show positive staining in the dsRNA-treated
whole hearts (Fig. 6F, G).
Immunofluorescence confocal microscopy also has
showed the decrease in tropomyosin expression in nor-
mal hearts that stopped beating after transfection with
double-stranded MIR for 4 days. In some of the hearts, the
loss of cells with positive tropomyosin protein staining
and organized myofibrils structure is nearly 100% in the
ventricular area of the heart tube (Fig. 7A, B). We observed
some cells in a random pattern that have positive green
signal from tropomyosin staining, but with a much lower
signal intensity. In hearts that stopped beating after 4 days
of transfection with double-stranded MIR, their tropomy-
osin staining was much weaker in general and there were
far fewer cells with positive staining for tropomyosin as
compared to the hearts from day 9. The high percentage of
cells with decreased tropomyosin expression in the whole
heart tube after double-stranded MIR transfection is due
to our high efficiency of transfection of double-stranded
MIR into the heart cells, as described in the Materials and
Methods section. The efficiency in knocking-down tropo-
myosin expression as well as visualization of its differen-
tial expression was likely due to direct exposure of
cardiomyocytes to the MIR in solution because of an
absence of the epicardial layer in hearts at stage 37/38
[29].
These findings strongly suggest that the MIR gene is essen-
tial for myofibrillogenesis and heart development in nor-
mal embryonic hearts.
The transcription levels of ATmC-1 and 2 (alpha-TM) and 
ATmC-3 (TM4) genes are not altered by short term but 
Myofibril morphological examinations Figure 7
Myofibril morphological examinations. Normal embryonic hearts treated with double-stranded MIR for 4 days show a 
dramatic reduction in tropomyosin protein and myofibrils. Hearts scanned here with dsRNA transfection already have stopped 
beating at the time of fixation. Hearts incubated with mock transfection (no dsRNA) show abundant staining of tropomyosin 
and organized myofibril structures (A). Hearts transfected by dsRNA show almost no detectable expression of tropomyosin in 
the whole area of the ventricle (B). (Magnification: 60 ×).
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decrease after long term MIR knockdown following 
double-stranded RNA treatment
On treatment with ds-RNA, we observed that a significant
number of hearts stopped beating at days 3 and 4. To
determine the transcriptional levels of tropomyosin genes
following ds-RNA treatment, we collected the total RNA
from hearts treated with dsRNA and the negative controls
(cultured in Lipofectin/Steinberg's solution only, with no
dsRNA) after a 2-day transfection period with dsRNA (24
to 48 hours before significant decreases of tropomyosin
protein were observed). Gene expression levels were then
analyzed for both alpha-tropomyosin and TM4 type tro-
pomyosin as well as the endogenous MIR. We observed
that the endogenous expression of MIR was knocked
down about 80% in normal hearts 36 or 84 hours after
dsRNA transfection compared to the negative controls
(Fig. 8A). It should be noted that a gradual decrease of
MIR expression in untreated hearts was observed relative
to in vitro culture times which is consistent with our ear-
lier reports that MIR expression decreases progressively
during in vivo development [7]. Two of the major iso-
forms of tropomyosin expressed in axolotl hearts alpha-
tropomyosin (ATmC-1 and ATmC-2) and TM4 type tro-
pomyosin (ATmC-3), interestingly, were not significantly
reduced at the transcriptional level after a short period of
treatment with double-stranded MIR (Fig. 8).
However, after collecting RNA samples from hearts organ-
cultured for 9 days with either dsRNA or the no RNA con-
trols, we found that both the alpha-tropomyosin and TM4
type tropomyosin decreased in mRNA levels in our real-
time RT-PCR assays (Fig. 8). No significant changes in the
tropomyosin expression levels were observed in dsRNA-
treated hearts compared to the mock-transfected normal
hearts (no dsRNA) in alpha-tropomyosin (ATmC-1 and
ATmC-2) and TM4 type tropomyosin total RNA tran-
scripts at either 36 hours or 84 hours post-transcription. A
confirmation of the effect of double-stranded RNA trans-
fection was shown by down regulation of the endogenous
MIR to 1/4th (36 hours) to 1/5th (84 hours) dsRNA trans-
fection (Fig. 8A). Decreased expression levels for both
types of tropomyosin have also been detected in the 9-
day-cultured hearts compared to the hearts cultured for
only 36 or 84 hours.
These results indicate that MIR possibly influences tropo-
myosin gene expression by an indirect regulatory mecha-
nism. We also showed that decreasing the tropomyosin
protein level in normal hearts after double-stranded MIR
treatment is not due to changes of alpha-tropomyosin
(ATmC-1 and 2) or TM4 tropomyosin (ATmC-3) mRNAs,
but rather due to a failed translational or posttranslational
control.
Determination of myofibril protein expression Figure 8
Determination of myofibril protein expression. Real-
time RT-PCR confirms the knockdown of endogenous MIR 
(A) in the normal hearts but shows no significant difference 
at the level of the transcripts of alpha- (B) and TM4 type tro-
pomyosin (C) transcripts in the normal hearts treated with 
double-stranded MIR (dsRNA-) for 36 hours or 84 hours. 
However, both alpha- and TM4 type tropomyosin transcripts 
in the normal hearts treated with dsRNA for 9 days show 
dramatic decreases to nearly 1/3 of the levels in control 
groups with hearts incubated in lipofectamine transfection 
medium only. MIR expression in 9-day-cultured hearts is not 
detectable.
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The reduced expression of tropomyosin may be related to 
the differential regulation of MIR of various tropomyosin 
isoforms in normal and mutant hearts
With the observation of normal control of tropomyosin
expression at the mRNA level in mutant hearts, we have
extended our studies of tropomyosin expression at the
protein level. To determine whether multiple isoforms of
tropomyosin exist in embryonic axolotl hearts and to ver-
ify if they are differentially expressed in mutant hearts, we
used two-dimensional Western blotting experiments.
Using a monoclonal antibody (CH1), developed to recog-
nize sarcomeric type tropomyosin specifically [30], we
have detected five different protein spots (tropomyosin
isoforms) from both normal and mutant embryonic
hearts at stages 36 to 42 (Fig. 9). All isoforms of tropomy-
osin detected by the CH1 antibody are located between pI
4 to 5 with molecular weight of approximately 38 kD. As
shown in the Fig. 9C, D, we have found that, the protein
levels of all the isoforms are significantly decreased in the
mutant hearts compared to the normals. The No. 2 pro-
tein spot is barely shown in the enlarged blot but we can
clearly see this spot in the overexposed film as shown in
the right top corner (inset) of Fig. 9D. With reference to
protein spot number 5, it was not detectable in either nor-
mal or mutant heart samples at stage 36 (initiation of nor-
mal heartbeat stage). However, at stage 42, the number 5
protein spot was prominent in normal heart samples but
nonexistent in mutant hearts.
As shown in Fig. 9, we have observed an isoform switch
between embryonic hearts at stage 36 (Fig. 9D) and stage
42 (Fig. 9G). The stage 36 hearts predominantly express
isoform 1 while the stage 42 hearts express isoforms 2 and
5. To further confirm the active translational activity for
tropomyosin proteins in mutant hearts, we have treated
the mutant hearts with the cysteine-protease inhibitor, N-
acetyl-leucine-leucine-norleucinal (LLnL, Calbiochem,
San Diego, CA). The LLnL is a membrane-permeable pro-
teinase inhibitor that inhibits Calpain and proteosome
and has been reported to affect tropomyosin turnover in
other cell culture systems [31]. All tropomyosin isoforms,
except for No. 1, show significant increases in both nor-
mal and mutant hearts after incubating with LLnL for 10
hours. Using another lyosomal cysteine proteinase inhib-
itor, E-64d (Sigma, St. Louis, WA), which inhibits Calpain
but not proteosome, interestingly showed increased
expression of all isoforms including No.1 (Fig. 9I). These
results suggest that different tropomyosin isoforms are
degraded by different proteinases.
To confirm the increased expression level of tropomyosin
protein after sense MIR treatment of mutant hearts, we
conducted 2D Western blotting experiments using protein
samples from mutant hearts treated with sense or anti-
sense MIR for 4 days. (Fig. 9D, H and 9J), show that anti-
sense MIR treatment decreases the amount of
tropomyosin isoform 1 in mutant hearts without altering
isoforms 3, 4 and 5. A significant increase of isoform 2,
one of the major isoforms of tropomyosin in the embry-
onic heart at stage 42, is also detected. However, an unex-
pected loss of isoform 5 is observed in the sense MIR-
treated mutant heart sample. These results unequivocally
prove that MIR post-transcriptionally controls tropomy-
osin expression in embryonic hearts. In normal and
mutant heart samples, irrespective of stage or MIR treat-
ment, isoform 4 is always detectable with negligible alter-
ation in expression, indicating that it probably has a
housekeeping function.
MIR promotes expression of myofibril structural protein 
genes
From the previous experiments it is clear that MIR has a
significant influence on the expression of tropomyosin in
the developing heart which is known to play a major role
in mechanically stabilizing actin filaments [32]. In this
investigation we extended our gene expression studies to
determine whether MIR promotes the expression of
myofibril structural genes other than tropomyosin, such
as, α-myosin heavy chain, myosin-binding C-protein and
cardiac troponin T and α-syntrophin (one of the dys-
trophin-associated proteins), in normal and mutant
hearts (Fig. 10). For the real-time RT-PCR experiments,
primer pairs for each gene were designed in the intron-
flanking exon sequences to avoid PCR amplifications
from genomic DNA contaminants. A significant increase
in the mRNA of α-MHC, C-protein, cTnT and α-syn-
trophin were observed after 36 hours of incubation of
mutant hearts (stage 37-38) with sense MIR, but not with
antisense RNA. However, the effects of MIR treatment
diminished after 72 hours, indicating possible degrada-
tion of MIR in the heart cells (Fig. 10G). On the other
hand, p53 and Msx-1 genes, both being cell differentia-
tion-related genes, show increased expression in the
mutant hearts after 72 hours of MIR treatment, indicating
an indirect or long term effect of MIR on promoting
embryonic cardiomyocyte differentiation.
In summary, there are three categories of myofibril struc-
tural genes that respond to the treatment of MIR differ-
ently at their mRNA level: 1) genes that can be quickly (36
hours) up-regulated in transcription by MIR sense RNA
treatment (α-MHC, C-protein, cTnT and α-syntrophin);
2) genes that can be slowly (72 hours) up-regulated by
MIR sense RNA treatment (p53 and Msx-1); and 3) genes
that are not affected by MIR treatment (cardiac actin, β-
syntrophin and ATmC-1, -2 and -3).
Discussion
Our research on the MIR gene has been the first to dem-
onstrate that a small RNA is involved in the regulation ofJournal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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Figure 9 (see legend on next page)Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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embryonic heart development in the cardiac mutant
(gene c) of Ambystoma mexicanum. In the case of the MIR
gene, since we now know that the MIR is a polyadenylated
RNA, there is reason to believe that it may function
through its unique secondary structure to promote myofi-
brillogenesis in the mutant hearts. We favor this hypothe-
sis for the following reasons: First, the RNA used for
rescuing experiments (either 650 nt full length or 166 nt
clone #4 RNA) was not processed for translation by cap-
ping or polyadenylation before it was added to the heart
cultures implying that it lacked necessary machinery for
translation inside the cells. The possibility that the active
RNA rescues mutant hearts by providing mRNA that is
translated is unlikely. Second, although there are several
small open reading frames (ORF) predicted for the full
length gene (the longest ORF is shown in Fig. 1), the
shortest RNA we have shown to preserve bioactivity (140
nt with 26 nt deleted from the 3' end of 166 nt Clone #4
sequence shown with an underline in Fig. 1) does not
cover the whole ORF [33]. Thus, the chance of this RNA
being translated in the cells is virtually nonexistent.
Recently, there have been numerous tissue-specific and
embryonic stem cell-expressed microRNAs cloned from
mouse, some of which are heart specific [34,35]. Prior to
our finding on the MIR [7,11] there had been no previ-
ously reported non-coding RNAs important for heart
development). In fact, the MIR gene appears to be the first
non-coding RNA that has been reported to be involved in
the process of anterior endoderm inducing precardiac
mesoderm to form functional cardiac muscle tissue [36].
Further characterization is underway to rule out the possi-
bility of MIR as being a typical miRNA and/or consider as
a piRNA [37-39] or some other unique regulatory RNA
molecule.
One of the long term objectives of our studies is to find
the mammalian homolog of the MIR gene and study
related pathways in mammals, including human.
Although some of the noncoding RNAs, such as some
micro RNAs, are conserved between species, there are oth-
ers that have many variations [40]. Based on sequence
similarity, we have not yet identified the mammalian MIR
homolog gene from a database search although we have
preliminary data indicating that both sheep heart [7] and
human heart (our unpublished data) contain functional
MIR homologs which are able to promote myofibrillogen-
esis and rescue the mutant axolotl hearts. Recently, Mum-
mery et al. [41] have indicated that there exists a very
similar, probably identical, induction mechanism for
mouse heart development from signals secreted from cul-
tured mouse visceral endoderm-like cells. This factor has
been found to be capable of promoting beating cardiomy-
ocyte differentiation and beating in human embryonic
stem cell cultures, indicating a non-protein factor secreted
from mouse visceral endoderm cells, possibly the mouse
homolog of our MIR gene. Thus, these results and findings
from our studies in the animal model, Ambystoma mexica-
num, suggest that the relationship between endoderm and
heart induction is genetically conserved across the verte-
brate species.
We have previously demonstrated that the MIR (166 nt
core sequence) can bind to more than one protein. The
MIR gene and its binding proteins are apparently involved
in the regulation of tropomyosin expression [7]. Prior to
current studies, it was not clear whether the failure of tro-
pomyosin expression in mutant hearts takes place at the
transcriptional level or the translational level and which
isoform(s) of tropomyosin is/are significantly reduced in
the mutant embryonic hearts. Our results in this study
prove unequivocally that the MIR and, perhaps, its bind-
ing protein(s) work together to regulate tropomyosin
expression translationally or posttranslationally in the
mutant hearts since our studies did not detect transcrip-
tional or splicing pattern differences in tropomyosin
genes between normal and mutant embryonic hearts.
Moreover, sequencing of the full-length cDNAs of both
Two-dimensional SDS-PAGE of embryonic heart proteins followed by Western Blotting using CH1 (anti-tropomyosin) anti- body Figure 9 (see previous page)
Two-dimensional SDS-PAGE of embryonic heart proteins followed by Western Blotting using CH1 (anti-tro-
pomyosin) antibody. Untreated stage 36 normal hearts (A); Untreated stage 36 mutant hearts (B); Enlarged figure from A 
for CH1-recognizable tropomyosin isoforms in untreated normal hearts (C); Enlarged figure from B for CH1-recognizable tro-
pomyosin isoforms in untreated normal hearts (D); The top right corner after overexposure of the same blot as D shows that 
mutant hearts are expressing isoform 2 as well as isoforms 1, 3 and 4. Mutant hearts at this stage are expressing all of the iso-
forms as normal hearts at much lower levels along with an extra isoform (5) which is detectable only at later developmental 
stages in normal hearts (G); Stage 36 normal hearts incubated with LLnL for 10 hours. The left bottom corner shows the less 
exposed image after Western blotting on the same sample, clearly showing increased protein concentration for isoform 2, 3 
and 4 but not for 1 (E); Stage 36 mutant hearts incubated with LLnL for 10 hours. Increasing of protein concentration for iso-
form 3, 4 and 5 is clearly detected but not for 1 (F); Untreated stage 42 normal hearts (G); Stage 42 normal hearts incubated 
with E64d for 10 hours (I); Protection for isoform 1 is detected. Stage 36 mutant hearts treated by antisense MIR for 4 days 
(H); Stage 36 mutant hearts treated by sense MIR for 4 days (J); A significant increase in spot density for isoform 2 is detected 
when compared to untreated mutant hearts at the same stage (D).Journal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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Real-time RT-PCR of myofibril genes on total RNA from stage 35-37 embryonic hearts treated by MIR Figure 10
Real-time RT-PCR of myofibril genes on total RNA from stage 35-37 embryonic hearts treated by MIR. Relative 
expression levels of different genes were compared after normalizing by beta-actin mRNA levels. 36A: antisense MIR treated 
for 36 hours; 36S: sense MIR treated for 36 hours; 72A: antisense MIR treated for 72 hours; 72S: sense MIR treated for 72 
hours; -/-: homozygous mutant hearts with no treatment; +/+: homozygous normal hearts with no treatment. Alpha-MHC (A), 
C-protein (B), cardiac troponin T (C), alpha-1-syntrophin (D), p53 (E), Msx-1 (F), beta-1-syntrophin (G), ATmC-3 (H), cardiac 
actin (I).
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alpha-tropomyosin and ATmC-3 from the embryonic
hearts of both normal and mutant axolotls showed no dif-
ferences reiterating the possible non-existence of splice
variants of these genes in mutant hearts.
In addition to its significance for studying the basic mech-
anisms of myofibrillogenesis, irregularities in tropomy-
osin expression have also been shown to have clinical
significance. There have been a number of reports indicat-
ing that familial cardiomyopathy can be caused by muta-
tions in the tropomyosin gene itself [42-44].
Homozygous alpha-TM knockout mice are embryonic
lethal [45]. Therefore, the cardiac mutant axolotl, with its
deficiency in tropomyosin and its ability to be corrected,
is potentially a very important model system for studying
regulation of tropomyosin isoforms. It is clear from our
analyses of the cardiac lethal mutant axolotl, that gene 'c'
does not control early heart morphogenesis since the
heart appears to form normally at pre-heartbeat stages
[46]. However, the expression of tropomyosin is signifi-
cantly reduced at the heartbeat stage (stage 35) [47].
Moreover, fewer isoforms of tropomyosin are detectable
in embryonic mutant hearts by two-dimensional gel elec-
trophoresis as compared to normal hearts [4]. This tropo-
myosin deficiency is intriguing given the current
understanding of tropomyosin genetics and expression
[16,17,25,44,48]. Despite these numerous studies, the
mechanisms of tropomyosin gene regulation in cardiac
tissues are not completely understood.
In addition to the identification of tissue specific tran-
scription factors that regulate different tropomyosin gene
transcription and specific intron/exon splicing regulatory
sequences and factors that control alternative splicing,
there are numerous recent findings that show both trans-
lational and posttranslational (sorting and protein turno-
ver) control on tropomyosin proteins. For example,
Rethinasamy et al. [45] have shown that translational reg-
ulation plays a major role in tropomyosin expression. In
heterozygous knockout mouse hearts with a 50% reduc-
tion in cardiac muscle α-TM mRNA, no compensatory
increase in transcript levels were found for striated muscle
β-TM or TM-30 isoforms. However, normal amounts of
striated muscle α-TM protein are produced and integrated
into the myofibril, suggesting a mechanism for adjusting
translational levels in functioning mouse hearts.
Besides the sorting mechanism for specific tropomyosin
isoform subcellular localization, proteinase degradation
is another important regulatory mechanism in the post-
translational control of tropomyosin. In non-muscle nor-
mal rat kidney (NRK) cells, it has been reported that large
molecular weight tropomyosin proteins are degraded
faster than smaller molecular weight tropomyosin pro-
teins indicating different proteinases are involved in their
proteolysis [31]. The stress fiber component tropomyosin
degradation in normal cells or under growth factor treat-
ment can be blocked by LLnL, a proteinase inhibitor to
lysosomal cathepsins B and L, cytoplasmic calpains I and
II [49] and proteasomes. However, using inhibitors that
block calpains but not proteasomes does not block TM
degradation [50]. These results indicate that striated mus-
cle myofibril structural tropomyosins, stress-fiber high
molecular weight tropomyosins and small molecular
weight non-muscle tropomyosins are degraded by differ-
ent proteinases within the cell. In our studies using axolotl
heart tissue, we have also shown that LLnL can prevent
degradation of some striated muscle tropomyosin pro-
teins (CH1 antibody recognizable) but not all, especially
isoform number 1 that has increased expression along
with heart development but has not been protected from
the degradation by LLnL. Another Proteinase inhibitor, E-
64d, inhibits Calpain activities but not proteosome activ-
ites and thus protects a different subset of tropomyosin
isoforms including isoform number 1 in the embryonic
hearts.
In our mutant axolotl system, the decreased translational
level of tropomyosin protein, abnormal tropomyosin
sorting and significantly higher rates of protein degrada-
tion of the tropomyosin protein could all exist as a poten-
tial foundation for this mutant phenotype. However,
recent studies on mutant hearts with normal ATmC-1,
ATmC-2 and ATmC-3 tropomyosin cDNA transfected
constructs, clearly show reorganization of myofibril struc-
tures, indicating the possible existence of a sorting mech-
anism in mutant cardiomyocytes [20,51].
Two possible mechanisms by which MIR promotes tropo-
myosin synthesis and myofibrillogenesis in the mutant
axolotl hearts might include:
1. A mechanism whereby the MIR enters the mutant heart
cells, is transported into the nucleus, perhaps together
with its binding protein(s) [7], and promotes gene tran-
scription of the various myofibril components. The MIR
could as well regulate RNA splicing processes for these
genes as indicated in our studies on cardiac troponin T
[23]. The myofibrillogenesis is thus promoted with
increased expression of building blocks of myofibrillar
proteins. While the nascent myofibrillar structures may
incorporate tropomyosin proteins and protect them from
being degraded in MIR treated hearts, it is possible that
those proteins, existing in unprotected monomer form in
the untreated hearts, get degraded by unknown protein-
ase(s).
2. A second possibility might be that MIR and its binding
proteins promote gene expression followed by translation
of protein products that facilitate the translation of theJournal of Biomedical Science 2009, 16:81 http://www.jbiomedsci.com/content/16/1/81
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mRNA of tropomyosin and possibly others, thus provid-
ing the essential building blocks for myofibrillogenesis. It
is very unlikely that MIR and its binding proteins directly
promote tropomyosin translation, since it takes 3-4 days
after MIR transfection before increased tropomyosin
expression and myofibril formation is observed in the
mutant heart cells.
Recent studies show that short double-stranded RNA
duplexes trigger post-transcriptional gene silencing and
can also induce epigenetic silencing of genes at the level of
transcription [52]. They can also interact at promoter
regions and can activate or repress gene expression [53] or
affect translation without affecting transcription [54].
While studies on siRNAs and miRNAs were extensively
conducted in a wide variety of systems, comparatively, no
remarkable studies were reported on small RNAs espe-
cially those that are similar to MIR. Recently, Makarev et
al. [55] identified several miRNAs and small RNAs from
adult newt eye, 42 of which have no similarity with
known miRNAs or piRNAs. Our studies also clearly sug-
gest that our MIR has no sequence homology with any of
these known RNAs. Furthermore, none of the known
small RNAs, to our knowledge, have been shown to regu-
late myofibrillogenesis similar to MIR. However, miRNAs
on the other hand have been implicated as regulators of
transcription as well as translation in a wide variety of sys-
tems [54,56].
Although such reports indicate the regulatory role of dif-
ferent small RNAs at the transcription and/or translational
levels, the underlying molecular mechanisms, however,
are still poorly understood. Whatever the final mecha-
nism of action of MIR turns out to be, it is very clear that
MIR promotes tropomyosin synthesis and myofibrillo-
genesis in the mutant hearts and is essential for tropomy-
osin expression and myofibrillogenesis in normal hearts.
We are conducting several experiments to isolate func-
tional mouse/human homologues of MIR for further
characterization. We assume also that MIR, or an MIR-
type functional homologue, is involved in cardiomyocyte
precursor cell differentiation in all vertebrate species.
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